Literature DB >> 28628105

Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome.

Grant J Logan1, Allison P Dane1, Claus V Hallwirth1, Christine M Smyth1, Emilie E Wilkie2,3, Anais K Amaya1, Erhua Zhu1, Neeta Khandekar1, Samantha L Ginn1, Sophia H Y Liao1, Sharon C Cunningham1, Natsuki Sasaki1, Martí Cabanes-Creus4,5, Patrick P L Tam3, David W Russell6,7, Leszek Lisowski4,8, Ian E Alexander1,9.   

Abstract

Vectors based on adeno-associated virus type 2 (AAV2) are powerful tools for gene transfer and genome editing applications. The level of interest in this system has recently surged in response to reports of therapeutic efficacy in human clinical trials, most notably for those in patients with hemophilia B (ref. 3). Understandably, a recent report drawing an association between AAV2 integration events and human hepatocellular carcinoma (HCC) has generated controversy about the causal or incidental nature of this association and the implications for AAV vector safety. Here we describe and functionally characterize a previously unknown liver-specific enhancer-promoter element in the wild-type AAV2 genome that is found between the stop codon of the cap gene, which encodes proteins that form the capsid, and the right-hand inverted terminal repeat. This 124-nt sequence is within the 163-nt common insertion region of the AAV genome, which has been implicated in the dysregulation of known HCC driver genes and thus offers added insight into the possible link between AAV integration events and the multifactorial pathogenesis of HCC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28628105     DOI: 10.1038/ng.3893

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  57 in total

1.  Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS.

Authors:  M A Zanta-Boussif; S Charrier; A Brice-Ouzet; S Martin; P Opolon; A J Thrasher; T J Hope; A Galy
Journal:  Gene Ther       Date:  2009-03-05       Impact factor: 5.250

2.  A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication.

Authors:  R J Samulski; L S Chang; T Shenk
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

3.  Dexamethasone inhibits the binding of nuclear factors to the IL-5 promoter in human CD4 T cells.

Authors:  A Quan; M N McCall; W A Sewell
Journal:  J Allergy Clin Immunol       Date:  2001-09       Impact factor: 10.793

4.  The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification.

Authors:  R Heilbronn; A Bürkle; S Stephan; H zur Hausen
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus/piggyBac transposase gene delivery system.

Authors:  Sharon C Cunningham; Susan M Siew; Claus V Hallwirth; Christine Bolitho; Natsuki Sasaki; Gagan Garg; Iacovos P Michael; Nicola A Hetherington; Kevin Carpenter; Gustavo de Alencastro; Andras Nagy; Ian E Alexander
Journal:  Hepatology       Date:  2015-05-23       Impact factor: 17.425

7.  Gene delivery to the juvenile mouse liver using AAV2/8 vectors.

Authors:  Sharon C Cunningham; Allison P Dane; Afroditi Spinoulas; Grant J Logan; Ian E Alexander
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

8.  Adeno-associated virus finds its disease.

Authors:  David W Russell; Markus Grompe
Journal:  Nat Genet       Date:  2015-10       Impact factor: 38.330

9.  Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults.

Authors:  H D Mayor; S Drake; J Stahmann; D M Mumford
Journal:  Am J Obstet Gynecol       Date:  1976-09-01       Impact factor: 8.661

10.  Analysis Tool Web Services from the EMBL-EBI.

Authors:  Hamish McWilliam; Weizhong Li; Mahmut Uludag; Silvano Squizzato; Young Mi Park; Nicola Buso; Andrew Peter Cowley; Rodrigo Lopez
Journal:  Nucleic Acids Res       Date:  2013-05-13       Impact factor: 16.971

View more
  28 in total

Review 1.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

Review 2.  Update on clinical gene therapy for hemophilia.

Authors:  George Q Perrin; Roland W Herzog; David M Markusic
Journal:  Blood       Date:  2018-12-17       Impact factor: 22.113

3.  AAV6 Is Superior to Clade F AAVs in Stimulating Homologous Recombination-Based Genome Editing in Human HSPCs.

Authors:  Amanda M Dudek; Matthew H Porteus
Journal:  Mol Ther       Date:  2019-09-12       Impact factor: 11.454

4.  Flies in the ointment: AAV vector preparations and tumor risk.

Authors:  Junping Zhang; Xiangping Yu; Roland W Herzog; R Jude Samulski; Weidong Xiao
Journal:  Mol Ther       Date:  2021-08-26       Impact factor: 12.910

Review 5.  The role of telomeres and telomerase in cirrhosis and liver cancer.

Authors:  Jean-Charles Nault; Massih Ningarhari; Sandra Rebouissou; Jessica Zucman-Rossi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06-28       Impact factor: 46.802

6.  ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice.

Authors:  Silvere Pagant; Marshall W Huston; Luciana Moreira; Lin Gan; Susan St Martin; Scott Sproul; Michael C Holmes; Kathleen Meyer; Thomas Wechsler; Robert J Desnick; Makiko Yasuda
Journal:  Mol Ther       Date:  2021-03-26       Impact factor: 11.454

Review 7.  Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.

Authors:  Julia Fakhiri; Dirk Grimm
Journal:  Mol Ther       Date:  2021-04-05       Impact factor: 11.454

Review 8.  Genomics of Viral Hepatitis-Associated Liver Tumors.

Authors:  Camille Péneau; Jessica Zucman-Rossi; Jean-Charles Nault
Journal:  J Clin Med       Date:  2021-04-22       Impact factor: 4.241

9.  AAV Joins the Rank of Genotoxic Vectors.

Authors:  Utpal P Davé; Kenneth Cornetta
Journal:  Mol Ther       Date:  2021-01-20       Impact factor: 11.454

10.  Promoterless, Nuclease-Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia.

Authors:  Randy J Chandler; Leah E Venturoni; Jing Liao; Brandon T Hubbard; Jessica L Schneller; Victoria Hoffmann; Susana Gordo; Shengwen Zang; Chih-Wei Ko; Nelson Chau; Kyle Chiang; Mark A Kay; Adi Barzel; Charles P Venditti
Journal:  Hepatology       Date:  2021-05-21       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.